GL1X · GenesisL1 explorer

MolNFT v1 · #61502 · protein

Crystal structure of the complex between mmp-8 and a non-zinc chelating inhibitor

3DNG · Neutrophil collagenase: “Crystal structure of the complex between mmp-8 and a non-zinc chelating inhibitor”. X-ray diffraction, 3 ligands (AXA, CA, ZN), 2 pockets (best druggability 0.74). MolNFT v1 #61502 on GenesisL1: 3D…

PDB
3DNG
Type
protein
Length
326 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Neutrophil collagenase
EC
3.4.24.34
UniProt
P22894
Ligands
AXA, CA, ZN
Pockets
2 · best druggability 0.74

Structure

x-ray diffraction · 1 distinct chain · 25% helix, 17% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
A, BNeutrophil collagenase (EC 3.4.24.34)protein16325% helix, 17% strandP22894

Ligands and binding sites

  • AXA · (5S)-5-(2-amino-2-oxoethyl)-4-oxo-N-[(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)methyl]-3,4,5,6,7,8-hexahydro[1]benzothieno[2,3-d]pyrimidine-2-carboxamide · ligand · 2 copies · chains A, B
  • CA · Calcium ion · metal · 4 copies · chains A, B
  • ZN · Zinc ion · metal · 4 copies · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

2 pockets found on a 1 Å grid, 2 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
17200.740.7970AXA
22620.650.8234AXA

Interfaces

1 interface between chains.

  • A–B · 379 Ų buried · 4 hydrogen bonds · protein-protein

Compared structures

  • 3DNG · Crystal structure of the complex between MMP-8 and a non-zinc chelating inhibitor · the same entry in another collection · chain A against A, TM-score 1.00
  • P22894 · AlphaFold monomer V2.0 prediction for neutrophil collagenase (P22894) · a predicted model of the same protein · chain A against A, TM-score 0.97

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.